Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.40    3.60 (2.36%)
Bid:
156.20
Ask:
156.60
Spread: 0.40 (0.256%)
Market Cap: £895.10m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM / Interim Management Statement

27 Apr 2016 07:00

ELEMENTIS PLC - AGM / Interim Management Statement

ELEMENTIS PLC - AGM / Interim Management Statement

PR Newswire

London, April 26

27 April 2016

AGM / Interim Management Statement

Elementis plc (ELM.L, the “Company" or the “Group"), the Global Specialty Chemicals Company, today issues its Interim Management Statement for the three months ended 31 March 2016.

Commenting on the Company’s performance Group Chief Executive, Paul Waterman, said: “During my first two months at Elementis I have been impressed by the quality of our people and the resilience of our business model. This is best exemplified by the sustained level of contribution margins in Specialty Products, the relative stability of the Chromium business in North America and the Group’s strong cash generation. Although some markets continue to be challenging and we are cycling against a stronger first quarter in 2015, we are proactively managing our margins and cost base to ensure that our performance for the year remains in line with management expectations.”

In Specialty Products, sales performance in coatings and personal care was satisfactory, while currency and lower oilfield sales resulted in total sales being 7 per cent below the same period last year. The following comments by division refer to constant currency sales:

In coatings additives, sales in North America were similar to the previous year as sales of decorative products from the New Martinsville plant continued to make good progress, while industrial sales remained subdued due to the impact of the stronger dollar on consumer exports, as previously reported. Sales in Europe were 1 per cent higher, while sales in Asia Pacific were 1 per cent lower, following the destocking and adjustment that took place in the Chinese economy in the second quarter of 2015. Sales to Latin America represent 5 per cent of total coatings sales and were 9 per cent lower than the previous year due to economic weakness in that region, particularly in Brazil.

In personal care, sales were 4 per cent higher than the previous period, as the business continued to benefit from geographic expansion and new product sales.

Sales in oilfield drilling were broadly in line with the quarterly sales run rate experienced in the second half of 2015, following the sharp downturn in North American demand that took place in the early part of 2015. Consequently, sales for the current quarter were 37 per cent below the same quarter last year.

As anticipated, Chromium sales for the first quarter were 11 per cent lower than the previous year, as market conditions outside of North America continued to be challenging. Although sales in North America were lower by 5 per cent, this is largely due to order timing and sales for the first six months of the year are expected to be in line with the same period last year. Sales outside of North America were 19 per cent lower than the previous year, with volumes lower by 6 per cent and pricing lower by 13 per cent.

The Group’s balance sheet remains strong and is again expected to be in a net cash position at the end of the year which, under our dividend policy, will continue to provide shareholders with attractive returns.

ENDS

Enquiries:

Elementis Paul Waterman, Chief Executive Brian Taylorson, Finance Director+ 44 (0) 207 067 2999
FTI Consulting Deborah Scott Matthew Cole+ 44 (0) 203 727 1000
Date   Source Headline
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding
6th Sep 202212:52 pmRNSDirector Declaration
5th Sep 20224:14 pmRNSAdditional Listing
1st Sep 202212:39 pmRNSHolding(s) in Company
1st Sep 20229:15 amRNSBlock listing Interim Review
1st Sep 20229:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.